Disease:
Atrial Fibrillation

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA No VIP available CYP2C19 *1 N/A N/A N/A
No VIP available CA No VIP available CYP2C19 *2 N/A N/A N/A
No VIP available CA No VIP available CYP2C19 *3 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C9 *1 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C9 *2 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C9 *3 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C9 *25 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs10033464 NC_000004.11:g.111720761T>G, NC_000004.12:g.110799605T>G, rs45629363, rs58654210
T > G
SNP
No VIP available No Clinical Annotations available VA
rs1057868 NC_000007.13:g.75615006C>T, NC_000007.14:g.75985688C>T, NG_008930.1:g.75587C>T, NM_000941.2:c.1508C>T, NP_000932.3:p.Ala503Val, NW_003871064.1:g.3514924C>T, XM_005250459.1:c.1508C>T, XM_005250460.1:c.1205C>T, XM_005250461.1:c.932C>T, XM_005277600.1:c.1508C>T, XM_005277601.1:c.1205C>T, XM_005277602.1:c.932C>T, XP_005250516.1:p.Ala503Val, XP_005250517.1:p.Ala402Val, XP_005250518.1:p.Ala311Val, XP_005277657.1:p.Ala503Val, XP_005277658.1:p.Ala402Val, XP_005277659.1:p.Ala311Val, rs17840495, rs17846082, rs17859083, rs3198400, rs57699079
C > T
SNP
A503V
No VIP available No Clinical Annotations available VA
rs1057910 NC_000010.10:g.96741053A=, NC_000010.10:g.96741053A>C, NC_000010.11:g.94981296A=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NG_008385.1:g.47639A>C, NM_000771.3:c.1075A=, NM_000771.3:c.1075A>C, NP_000762.2:p.Ile359=, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, XM_005269575.1:c.1075A>C, XP_005269632.1:p.Ile359=, XP_005269632.1:p.Ile359Leu, rs17847042, rs3198471, rs61212474
A > C
SNP
I359L
No VIP available No Clinical Annotations available VA
rs1801252 NC_000010.10:g.115804036A>G, NC_000010.11:g.114044277A>G, NG_012187.1:g.5231A>G, NM_000684.2:c.145A>G, NP_000675.1:p.Ser49Gly, rs12720482, rs3740152
A > G
SNP
S49G
No VIP available No Clinical Annotations available VA
rs1801253 NC_000010.10:g.115805056G>C, NC_000010.11:g.114045297G>C, NG_012187.1:g.6251G>C, NM_000684.2:c.1165G>C, NP_000675.1:p.Gly389Arg, rs12718339, rs17091259, rs28365052, rs59130083
G > C
SNP
G389R
No VIP available No Clinical Annotations available VA
rs1805123 NC_000007.13:g.150645534T>A, NC_000007.13:g.150645534T>G, NC_000007.14:g.150948446T>A, NC_000007.14:g.150948446T>G, NG_008916.1:g.34481A>C, NG_008916.1:g.34481A>T, NM_000238.3:c.2690A>C, NM_000238.3:c.2690A>T, NM_172057.2:c.1670A>C, NM_172057.2:c.1670A>T, NP_000229.1:p.Lys897Met, NP_000229.1:p.Lys897Thr, NP_742054.1:p.Lys557Met, NP_742054.1:p.Lys557Thr, XM_011516185.1:c.2390A>C, XM_011516185.1:c.2390A>T, XM_011516186.1:c.2690A>C, XM_011516186.1:c.2690A>T, XP_011514487.1:p.Lys797Met, XP_011514487.1:p.Lys797Thr, XP_011514488.1:p.Lys897Met, XP_011514488.1:p.Lys897Thr, rs2968861, rs8179016
T > G
SNP
K897T
No VIP available CA VA
rs2108622 NC_000019.10:g.15879621C>T, NC_000019.9:g.15990431C>T, NG_007971.2:g.23454G>A, NM_001082.4:c.1297G>A, NP_001073.3:p.Val433Met, rs116975254, rs52819608, rs57319528
C > T
SNP
V433M
No VIP available No Clinical Annotations available VA
rs2200733 NC_000004.11:g.111710169C>T, NC_000004.12:g.110789013C>T, rs61314916
C > T
SNP
No VIP available CA VA
rs2244613 NC_000016.10:g.55810697G>T, NC_000016.9:g.55844609G>T, NG_012057.1:g.27467C>A, NM_001025194.1:c.1168-33C>A, NM_001025195.1:c.1171-33C>A, NM_001266.4:c.1165-33C>A, NW_003315945.1:g.34574G>T, XM_005255774.1:c.1168-33C>A, XM_005276867.1:c.1168-33C>A, rs61164855, rs72486000
G > T
SNP
No VIP available CA VA
rs2592551 NC_000002.11:g.85780131G>A, NC_000002.12:g.85553008G>A, NG_011811.2:g.13527C>T, NM_000821.6:c.1218C>T, NM_001142269.3:c.1047C>T, NP_000812.2:p.Arg406=, NP_001135741.1:p.Arg349=, XM_005264259.1:c.1218C>T, XM_005264259.3:c.1218C>T, XM_011532764.1:c.396C>T, XM_011532765.1:c.396C>T, XP_005264316.1:p.Arg406=, XP_011531066.1:p.Arg132=, XP_011531067.1:p.Arg132=, XR_939677.1:n.1283C>T, rs118075290, rs61110673
G > A
SNP
R406R
No VIP available CA No Variant Annotations available
rs28371685 NC_000010.10:g.96740981C>T, NC_000010.11:g.94981224C>T, NG_008385.1:g.47567C>T, NM_000771.3:c.1003C>T, NP_000762.2:p.Arg335Trp, XM_005269575.1:c.1003C>T, XP_005269632.1:p.Arg335Trp, rs60219528
C > T
SNP
R335W
No VIP available CA No Variant Annotations available
rs28371686 NC_000010.10:g.96741058C>G, NC_000010.11:g.94981301C>G, NG_008385.1:g.47644C>G, NM_000771.3:c.1080C>G, NP_000762.2:p.Asp360Glu, XM_005269575.1:c.1080C>G, XP_005269632.1:p.Asp360Glu, rs57527516
C > G
SNP
D360E
No VIP available No Clinical Annotations available VA
rs2868177 NC_000007.13:g.75589903A>G, NC_000007.14:g.75960585A>G, NG_008930.1:g.50484A>G, NM_000941.2:c.188+6405A>G, NW_003871064.1:g.3489821A>G, XM_005250459.1:c.188+6405A>G, XM_005250461.1:c.-264+6405A>G, XM_005277600.1:c.188+6405A>G, XM_005277602.1:c.-264+6405A>G, rs10375158, rs59093849, rs61116122
A > G
SNP
No VIP available CA VA
rs4148738
C > T
SNP
No VIP available CA No Variant Annotations available
rs7900194 NC_000010.10:g.96702066G>A, NC_000010.11:g.94942309G>A, NG_008385.1:g.8652G>A, NM_000771.3:c.449G>A, NP_000762.2:p.Arg150His, XM_005269575.1:c.449G>A, XP_005269632.1:p.Arg150His, rs57530584
G > A
SNP
R150H
No VIP available CA VA
rs8192935
N > G
SNP
No VIP available No Clinical Annotations available VA
rs887829 NC_000002.11:g.234668570C>T, NC_000002.12:g.233759924C>T, NG_002601.2:g.175181C>T, NG_033238.1:g.4652C>T, NM_000463.2:c.-364C>T, NM_001072.3:c.862-7110C>T, NM_007120.2:c.868-7110C>T, NM_019075.2:c.856-7110C>T, NM_019076.4:c.856-7110C>T, NM_019077.2:c.856-7110C>T, NM_019078.1:c.868-7110C>T, NM_019093.2:c.868-7110C>T, NM_021027.2:c.856-7110C>T, NM_205862.1:c.61-7110C>T, XR_241238.1:n.924-7110C>T, XR_241239.1:n.-342C>T, XR_241240.1:n.1023-7110C>T, XR_241241.1:n.942-7110C>T, rs12990609, rs34790730, rs36207722, rs386619532, rs61315639
C > T
SNP
No VIP available CA No Variant Annotations available
rs9332131 NC_000010.10:g.96709039delA, NC_000010.11:g.94949282delA, NG_008385.1:g.15625delA, NM_000771.3:c.817delA, NP_000762.2:p.Lys273Argfs, XM_005269575.1:c.817delA, XP_005269632.1:p.Lys273Argfs
A > -
indel
K273R
No VIP available No Clinical Annotations available VA
rs9923231 NC_000016.10:g.31096368C=, NC_000016.10:g.31096368C>T, NC_000016.9:g.31107689C=, NC_000016.9:g.31107689C>T, NG_011564.1:g.3588G=, NG_011564.1:g.3588G>A, NM_001311311.1:c.-1639G=, NM_001311311.1:c.-1639G>A, NM_024006.5:c.-1639G=, NM_024006.5:c.-1639G>A, NM_206824.2:c.-1639G=, NM_206824.2:c.-1639G>A, XM_005255568.1:c.-1639G=, XM_005255568.1:c.-1639G>A, XM_011545943.1:c.-1639G=, XM_011545943.1:c.-1639G>A, XM_011545944.1:c.-1252G=, XM_011545944.1:c.-1252G>A, XM_011545945.1:c.-1252G=, XM_011545945.1:c.-1252G>A, XR_243303.1:n.-990G=, XR_243303.1:n.-990G>A, XR_950848.1:n.-31G=, XR_950848.1:n.-31G>A, rs117572127, rs17878363, rs60511154
C > A
C > G
C > T
SNP
No VIP available No Clinical Annotations available VA
rs9934438 NC_000016.10:g.31093557G>A, NC_000016.9:g.31104878G>A, NG_011564.1:g.6399C>T, NM_001311311.1:c.174-136C>T, NM_024006.5:c.174-136C>T, NM_206824.2:c.173+1000C>T, XM_005255568.1:c.174-136C>T, XM_011545943.1:c.174-136C>T, XM_011545944.1:c.174-136C>T, XM_011545945.1:c.173+1000C>T, XR_243303.1:n.823-236C>T, XR_950848.1:n.962-136C>T, rs17641219
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names: 
Synonym
Atrial Fibrillations; Auricular Fibrillation; Auricular Fibrillations; Fibrillation, Atrial; Fibrillation, Auricular; Fibrillations, Atrial; Fibrillations, Auricular
PharmGKB Accession Id: PA443459
External Vocabularies

Curated Information ?

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
antiarrhythmics, class i and iii

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Curated Information ?

EvidenceDisease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stroke

Publications related to Atrial Fibrillation: 91

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of two variants of CYP450 oxidoreductase on the stable dose of acenocoumarol in a Spanish population. Pharmacogenomics. 2017. Tong Hoi Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients. European journal of clinical pharmacology. 2017. Wattanachai Nitsupa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial. Pharmacogenomics. 2017. Ragia Georgia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population. BMC research notes. 2016. Kudzi William, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients. Medicine. 2016. Misasi Silvia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ablatogenomics: can genotype guide catheter ablation for cardiac arrhythmias?. Pharmacogenomics. 2016. Roberts Jason D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP2C19 gene polymorphism on warfarin maintenance doses in patients with non-valvular atrial fibrillation. Gene. 2016. Zhang Hongshen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on european patients. British journal of clinical pharmacology. 2016. Gómez-Outes Antonio A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of dabigatran etexilate interindividual variability. Thrombosis research. 2016. Dimatteo Claudia, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PloS one. 2016. Duconge Jorge, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
microRNA expression changes after atrial fibrillation catheter ablation. Pharmacogenomics. 2015. Sardu Celestino, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation. British journal of clinical pharmacology. 2015. Blin Patrick, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Circulating atrial natriuretic peptide genetic association study identifies a novel gene cluster associated with stroke in whites. Circulation. Cardiovascular genetics. 2015. Pereira Naveen L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Examining rare and low-frequency genetic variants previously associated with lone or familial forms of atrial fibrillation in an electronic medical record system: a cautionary note. Circulation. Cardiovascular genetics. 2015. Weeke Peter, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. European journal of clinical pharmacology. 2015. Krishna Kumar Dhakchinamoorthi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. Pharmacogenomics. 2015. You Joyce H S. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transient left ventricular apical ballooning syndrome in a patient with allopurinol induced skin rash: A case report. International journal of cardiology. 2014. Bernards J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: A potential role of CYP4F2 and GGCX polymorphisms. Thrombosis research. 2014. Wypasek Ewa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics. 2014. Mizzi Clint, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics. 2014. Cerezo-Manchado Juan Jose, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Whole-exome sequencing in familial atrial fibrillation. European heart journal. 2014. Weeke Peter, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP4F2 1347 G > A & GGCX 12970 C > G polymorphisms: frequency in north Indians & their effect on dosing of acenocoumarol oral anticoagulant. The Indian journal of medical research. 2014. Rathore Saurabh Singh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atrial fibrillation genomics: Time to take the next step. Journal of the American College of Cardiology. 2014. Roden Dan M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm. Pharmacogenetics and genomics. 2013. Wolkanin-Bartnik Jolanta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A Randomized Trial of Genotype-Guided Dosing of Warfarin. The New England journal of medicine. 2013. Pirmohamed Munir, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Candidate Gene Approach to Identifying Rare Genetic Variants Associated with Lone Atrial Fibrillation. Heart rhythm : the official journal of the Heart Rhythm Society. 2013. Weeke Peter, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A Common Variant on Chromosome 4q25 is Associated With Prolonged PR Interval in Subjects With and Without Atrial Fibrillation. The American journal of cardiology. 2013. Kolek Matthew J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common SCN10A variants modulate PR interval and heart rate response during atrial fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2013. Delaney Jessica T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013. Paré Guillaume, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation. 2013. Ritchie Marylyn D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic mechanisms of atrial fibrillation: impact on response to treatment. Nature reviews. Cardiology. 2013. Darbar Dawood, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated gene GREM2 regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm. Disease models & mechanisms. 2013. Müller Iris I, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Evaluation of the effect of SNPs in CYP3A4 and CYP4F2 on the stable phenprocoumon and acenocoumarol maintenance dose. Journal of thrombosis and haemostasis : JTH. 2013. van Schie Rianne M F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common Genetic Polymorphism at 4q25 Locus Predicts Atrial Fibrillation Recurrence after Successful Cardioversion. Heart rhythm : the official journal of the Heart Rhythm Society. 2013. Parvez Babar, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects. Pharmacogenetics and genomics. 2013. Cavallari Larisa H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang. Lipids in health and disease. 2013. Kamali Xiayizha, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis. Clinical pharmacology and therapeutics. 2012. Danese E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common Atrial Fibrillation Risk Alleles at 4q25 Predict Recurrence after Catheter-based Atrial Fibrillation Ablation. Heart rhythm : the official journal of the Heart Rhythm Society. 2012. Benjamin Shoemaker M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C9 and VKORC1 gene polymorphism is inessential for bleeding development under conditions of oral application of anticoagulant acenocoumarol in Russian patients at high risk of thromboembolic complications. Bulletin of experimental biology and medicine. 2012. Sychev D V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A KCNJ8 mutation associated with early repolarization and atrial fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2012. Delaney Jessica T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients. Journal of clinical pharmacy and therapeutics. 2012. Smires F Z, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Race-Specific Impact of Atrial Fibrillation Risk Factors in Blacks and Whites in the Southern Community Cohort Study. The American journal of cardiology. 2012. Lipworth Loren, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Chromosome 4q25 Variants Are Genetic Modifiers of Rare Ion Channel Mutations Associated With Familial Atrial Fibrillation. Journal of the American College of Cardiology. 2012. Ritchie Marylyn D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Symptomatic Response to Antiarrhythmic Drug Therapy Is Modulated by a Common Single Nucleotide Polymorphism in Atrial Fibrillation. Journal of the American College of Cardiology. 2012. Parvez Babar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nature genetics. 2012. Ellinor Patrick T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. Pharmacogenomics. 2012. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thrombosis and haemostasis. 2012. Wei Meng, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clinical pharmacology and therapeutics. 2012. Liu Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Common beta1-Adrenergic Receptor Polymorphism Predicts Favorable Response to Rate-Control Therapy in Atrial Fibrillation. Journal of the American College of Cardiology. 2012. Parvez Babar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Validation of warfarin pharmacogenetic algorithms in clinical practice. Pharmacogenomics. 2012. Marin-Leblanc Mélina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of genome-wide association-identified variants for atrial fibrillation in African Americans. PloS one. 2012. Delaney Jessica T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. PloS one. 2012. Rathore Saurabh Singh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Clinical therapeutics. 2011. Cho Hyun-Jung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A. Chinese medical journal. 2011. Gao Lei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood. 2011. Gong Inna Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics. 2011. Mitchell Cathrine, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and nongenetic factors associated with warfarin doserequirements in Egyptian patients. Pharmacogenetics and genomics. 2011. Shahin Mohamed Hossam A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
KCNH2 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
VKORC1 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Owen Ryan P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart rhythm : the official journal of the Heart Rhythm Society. 2010. Yang Tao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. American journal of human genetics. 2010. Ritchie Marylyn D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clinical pharmacology and therapeutics. 2010. Cavallari L H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common variants in KCNN3 are associated with lone atrial fibrillation. Nature genetics. 2010. Ellinor Patrick T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins. Clinical pharmacology and therapeutics. 2009. Birkenfeld A L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. American heart journal. 2009. Watanabe Hiroshi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. Circulation. Cardiovascular genetics. 2009. Body Simon C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A genome-wide association study of acenocoumarol maintenance dosage. Human molecular genetics. 2009. Teichert Martina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine. 2009. Connolly Stuart J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. European journal of clinical pharmacology. 2009. Fuchshuber-Moraes Mateus, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics. 2009. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mutations in sodium channel beta1- and beta2-subunits associated with atrial fibrillation. Circulation. Arrhythmia and electrophysiology. 2009. Watanabe Hiroshi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood. 2009. Pérez-Andreu Virginia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of dronedarone on cardiovascular events in atrial fibrillation. The New England journal of medicine. 2009. Hohnloser Stefan H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Annals of internal medicine. 2009. Eckman Mark H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmia pharmacogenomics: methodological considerations. Current pharmaceutical design. 2009. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. The New England journal of medicine. 2008. Hodgson-Zingman Denice M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population. Pharmacogenetics and genomics. 2008. Ravn Lasse S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). European heart journal. 2008. Sinner Moritz F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clinical pharmacology and therapeutics. 2008. Limdi N A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. The New England journal of medicine. 2007. Singh Bramah N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart rhythm : the official journal of the Heart Rhythm Society. 2007. Darbar Dawood, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. Personalized medicine. 2007. Limdi Na, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA : the journal of the American Medical Association. 2007. Halonen Jari, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A common polymorphism in SCN5A is associated with lone atrial fibrillation. Clinical pharmacology and therapeutics. 2007. Chen L Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Clinics in geriatric medicine. 2006. Jacobs Laurie G. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenetics and genomics. 2005. Tai Guoying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. The New England journal of medicine. 2005. Rieder Mark J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
C825T polymorphism of the G-protein beta3 subunit gene and atrial fibrillation: association of the TT genotype with a reduced risk for atrial fibrillation. American heart journal. 2004. Schreieck Juergen, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2C9 genetic polymorphisms and warfarin. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2004. Redman Andrea R, et al. PubMed